Back

Latest Forum Topics / Luye Pharma

Post Reply

AsiaPharm Post Reply Rate topic
Nostradamus Supreme	18-Sep-2006 11:13        Nostradamus About Contact  Quote this Post!
x 0   x 0  Alert Admin	CIMB-GK has cut its target price for Asiapharm Group Ltd to $0.67 to reflect its expectations that the pharmaceutical company's earnings will be weaker over the next three years. "We lowered our earnings estimates for 2006-2008 by 17-19% as we factor-in a slower second half," CIMB-GK said in a note. However, the brokerage is keeping its "outperform" rating for the stock. CIMB-GK said a turnaround in the sales of Maitongna, an anti-inflammatory drug used in the fields of orthopaedics and neurology, and mergers and acquisitions would be grounds for a review of its target price for Asiapharm.
Useful To Me  Not Useful To Me
Nostradamus Supreme	12-Sep-2006 18:08        Nostradamus About Contact  Quote this Post!
x 0   x 0  Alert Admin	DBSV is advising a "hold" on the stock with a target price of $0.60, citing lack of catalysts in the near term and risks associated with investing in the government-controlled pharmaceutical sector. "We are concerned with risks to earnings rising in tandem with the government's restructuring efforts," the brokerage said in a note. "The ongoing restructuring in the China pharmaceutical sector will have a negative impact on earnings and recovery is expected only in 2007." DBSV said it expects Asiapharm's third-quarter earnings to remain weak as sales of its Maitongna - which is used as an anti-inflammatory drug in the fields of orthopaedics and neurology - will be dented by government-stipulated change in dosage while its planned merger and acquisition activities are unlikely to materialize in the near term.
Useful To Me  Not Useful To Me
Nostradamus Supreme	12-Sep-2006 14:01        Nostradamus About Contact  Quote this Post!
x 0   x 0  Alert Admin	OCBC has upgraded its rating on to "buy from "hold" as it believes the company's current share price is attractive after declining over 25% from July. "At its current price, we see an opportunity to buy into a cash-rich and R&D-focused company," OCBC said in a client note. "With a current cash stash of RMB411m, we think that Asiapharm has the financial strength to carry on with operations while patiently evaluating companies that are going for a bargain in this time of industry consolidation, " it added. OCBC noted Asiapharm has said the ongoing healthcare restructuring in China is likely to continue to exert short- to medium-term pressure on healthcare stocks. However, the brokerage believes the firm will continue to deliver a similar net profit margin of 26% as seen in the first half of this year. OCBC has a price target of $0.64.
Useful To Me  Not Useful To Me
Nostradamus Supreme	08-Sep-2006 17:15        Nostradamus About Contact  Quote this Post!
x 1   x 0  Alert Admin	Shares were lower because of the low profitability of Western medicines in China, dealers said. UOBKH said that the profitability of Western medicines has fallen to its lowest level yet in the first half, prompting it to rate the pharmaceutical industry in China as "underweight". "We believe that Asiapharm's weaker second-quarter results were a reflection of the general industrial condition," UOBKH analyst Leah Jiang said in a note. "As we expect the macro picture to remain broadly intact in the second half, we maintain our 'hold' call for Asiapharm, given its relatively higher valuation," she said. Another pharmaceutical firm, C&O was lower in afternoon trading.
Useful To Me  Not Useful To Me
allantanhc Veteran	08-Sep-2006 11:28        allantanhc About Contact  Quote this Post!
x 0   x 0  Alert Admin	Yes, chart wise shows that the counter is still on a  downtrend. May be better to wait till it stabilises before entry.
Useful To Me  Not Useful To Me
Sporeguy Elite	08-Sep-2006 10:03        Sporeguy About Contact  Quote this Post!
x 2   x 0  Alert Admin	Asia Pharm is on the third wave down to about 49 c support level and then will move up on 4th wave meeting resistance at 63 c and down on the 5th wave way below 49c.
Useful To Me  Not Useful To Me
kennylow Member	08-Sep-2006 09:54        kennylow About Contact  Quote this Post!
x 0   x 0  Alert Admin	hi all, pls advise is it a good price to go in now? At this level, i think no harm giving it a try since this co. is still making $$. If not, when should we wait till?
Useful To Me  Not Useful To Me
elizlow Senior	27-Aug-2006 08:56        elizlow About Contact  Quote this Post!
x 0   x 0  Alert Admin	Nostradamus thanks for yr advice. I am a new bie to this site and hope to learn  from gurus like u here. God bless.
Useful To Me  Not Useful To Me
Nostradamus Supreme	26-Aug-2006 21:14        Nostradamus About Contact  Quote this Post!
x 0   x 0  Alert Admin	Hi elizlow, It has support around $0.565. Failing which, further supports are at $0.54, $0.52 and $0.51.
Useful To Me  Not Useful To Me
YenYen Member	16-Aug-2006 01:22        YenYen About Contact  Quote this Post!
x 0   x 0  Alert Admin	Sorry .. Computer unstable after upgrading IE .. Anyway, wanted to say that Phillips Securities Research gave AsiaPharm a Hold recommendation with fair value at $0.64
Useful To Me  Not Useful To Me
YenYen Member	16-Aug-2006 01:10        YenYen About Contact  Quote this Post!
x 0   x 0  Alert Admin
Useful To Me  Not Useful To Me
Nostradamus Supreme	15-Aug-2006 19:02        Nostradamus About Contact  Quote this Post!
x 0   x 0  Alert Admin	AsiaPharm, one of the biggest makers of anti-inflammatory drugs in China, fell after the company posted a 16% fall in quarterly profit. AsiaPharm, the biggest pharmaceutical company listed in Singapore, earned 20.7 million yuan in the second quarter of the year, compared with 24.5 million yuan a year ago. CIMB-GK analyst Gary Ng said in a note on Tuesday that AsiaPharm's results were 5% below his expectations, but reiterated his "outperform" rating on the stock with a price target of S$0.84. "We are confident that AsiaPharm can achieve stronger 2H06 with sales gaining better traction, while enjoying sustainable higher margins," said Ng. I think wait a few more days before entering.
Useful To Me  Not Useful To Me
YenYen Member	15-Aug-2006 12:26        YenYen About Contact  Quote this Post!
x 1   x 0  Alert Admin	CIMB gave outperform rating. Target price: $0.84.
Useful To Me  Not Useful To Me
YenYen Member	15-Aug-2006 11:19        YenYen About Contact  Quote this Post!
x 1   x 0  Alert Admin	09:40 BROKER CALL - Singapore-listed Asiapharm target cut to 0.64 sgd - OCBC Above from POEMS' AFX headlines.
Useful To Me  Not Useful To Me
awesome Member	15-Aug-2006 10:54        awesome About Contact  Quote this Post! Style: Technical   Mood:
x 0   x 0  Alert Admin	Hi guys, What do you think of AsiaPharm's price now, it close at $0.7 yesterday. Is now a good time to go in ... ? Cheers. Jeremy
Useful To Me  Not Useful To Me
Nostradamus Supreme	05-May-2006 00:31        Nostradamus About Contact  Quote this Post!
x 0   x 0  Alert Admin	AsiaPharm is placing out 20m shares to Templeton Fund.
Useful To Me  Not Useful To Me
Gallen Senior	03-May-2006 08:31        Gallen About Contact  Quote this Post!
x 0   x 0  Alert Admin	Extracted from my blog http://kelongstocks.blogspot.com [B]Technical Analysis[/B] Asiapharm hit an intraday high of $1.02 on market talk that some fund managers were looking to acquire a stake in the company. Today's candlestick appears to be an bullish inverted hammer cum harami formation which signals a possible reversal in the downtrend. Need another bullish confirmation tomorrow. Bearish belt-hold candlestick broke the 84 cents support in previous session but prices gapped up and regained that support level. ...........continued at my blog
Useful To Me  Not Useful To Me
Gallen Senior	02-May-2006 20:46        Gallen About Contact  Quote this Post!
x 0   x 0  Alert Admin	Extracted from my blog http://kelongstocks.blogspot.com [b]Fundamental Analysis[/b] 1Q FY06 revenues and net profits increased by 8% and 32% respectively from 1Q FY05. Higher sales of pharmaceutical drugs were offset by lower export sales and sale of R&D results (due to more resources spent developing own products instead of third party products). Gross profit margins improved due to higher sales mix of pharmaceutical drugs, which commanded a higher gross profit margin. Costs were well contained as total costs rose 15% despite 19% increase in gross profits. Nevertheless, tax expenses for FY06 appear to be higher than the whole of FY05 (tax exemptions) and this will impact net margins. Asiapharm's growth will be driven by increased sales of pharmaceutical drugs (existings and new drugs/products to local and overseas markets) as well as potential M&A targets locally and overseas. .........continued at my blog
Useful To Me  Not Useful To Me

                                                         First   1-18 of 18   Last